The non-profit Multidisciplinary Association of Psychedelic Studies (MAPS) is leading the development of MDMA and has just reported top-line results from a phase 3 trial of the drug combined with ...

can be prescribed as a treatment for post-traumatic stress disorder (PTSD”. MDMA, which is commonly known as ecstasy, is currently classified as a Schedule I drug under the Controlled Substances ...

One day his psychiatrist handed him a copy of Michael Pollan's "How to Change Your Mind" and told him about the MAPS MDMA trials. "I had a very strong aversion to mind-altering drugs, because by ...

Amy Emerson, the CEO of MAPS, said the organization hopes such approval will “drive additional investment investment into new research in mental health.” MDMA is among a class of psychoactive ...

Maps' chief scientific officer Dr Berra Yazar-Klosinski said MDMA could be legalised and available for prescription by 2023 in the US, and this summer she plans to travel to Europe to begin the ...

Opinions expressed by Forbes Contributors are their own. A.J. Herrington is freelance writer covering weed news and culture. A California biopharmaceutical company has announced positive results ...

Partly, the news has been good. Really good, in fact. MDMA-assisted psychotherapy (MAP) for trauma has been studied by a top-notch group of researchers at several leading universities, and the ...

When the FDA turned down Lykos’ application for approval for its MDMA capsule along with psychological ... Association for Psychedelic Studies (MAPS), the parent company of Lykos, said he ...